SCHEMBL6985519

SCHEMBL6985519

CCOC(=O)C1C=Nc2c(c(OC)cc3cccnc23)C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RELA Q04206 2/20 0.38
NFKBIA P25963 1/20 0.38
SLC40A1 Q9NP59 1/20 0.37
KDM4E B2RXH2 5/20 0.37
LMNA P02545 5/20 0.37
HTT P42858 4/20 0.37
MAPK1 P28482 4/20 0.37
TP53 P04637 4/20 0.37
TDP1 Q9NUW8 3/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
MITF O75030 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
RAB9A P51151 3/20 0.36
PKM P14618 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6984797 0.87 MAPK1 (0.38) RELAKDM4ELMNAHTTMAPK1
SCHEMBL965521 0.86 SLC40A1 (0.40) RELANFKBIASLC40A1KDM4ELMNA
SCHEMBL1509799 0.82 SLC40A1 (0.37) RELANFKBIASLC40A1KDM4ELMNA
SCHEMBL6985195 0.80 ALDH1A1 (0.42) RELAKDM4ELMNAHTTMAPK1
SCHEMBL6987201 0.74 CCR1 (0.40) SLC40A1KDM4ELMNATP53L3MBTL1
SCHEMBL6981252 0.72 L3MBTL1 (0.38) RELASLC40A1KDM4ELMNAHTT
SCHEMBL967454 0.70 L3MBTL1 (0.39) RELAKDM4ELMNAHTTTDP1
SCHEMBL28560072 0.69 KDM4E (0.40) RELAKDM4EMAPK1TP53L3MBTL1
SCHEMBL29440753 0.69 TDP2 (0.38) RELAKDM4ELMNAMAPK1TP53
SCHEMBL6975182 0.69 L3MBTL1 (0.40) SLC40A1L3MBTL1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP claimed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US claimed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US claimed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP claimed
WO-1999021860-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 1999-08-05 WO claimed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO claimed
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 RELA 1194/4885NFKBIA 1421/4885SLC40A1 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.